Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 77

1.

Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma.

Unni AM, Lockwood WW, Zejnullahu K, Lee-Lin SQ, Varmus H.

Elife. 2015 Jun 5;4. doi: 10.7554/eLife.06907.

2.

Loss of MIG6 Accelerates Initiation and Progression of Mutant Epidermal Growth Factor Receptor-Driven Lung Adenocarcinoma.

Maity TK, Venugopalan A, Linnoila I, Cultraro CM, Giannakou A, Nemati R, Zhang X, Webster JD, Ritt D, Ghosal S, Hoschuetzky H, Simpson RM, Biswas R, Politi K, Morrison DK, Varmus HE, Guha U.

Cancer Discov. 2015 May;5(5):534-49. doi: 10.1158/2159-8290.CD-14-0750. Epub 2015 Mar 3.

PMID:
25735773
3.

Opinion: Addressing systemic problems in the biomedical research enterprise.

Alberts B, Kirschner MW, Tilghman S, Varmus H.

Proc Natl Acad Sci U S A. 2015 Feb 17;112(7):1912-3. doi: 10.1073/pnas.1500969112. No abstract available.

4.

A new initiative on precision medicine.

Collins FS, Varmus H.

N Engl J Med. 2015 Feb 26;372(9):793-5. doi: 10.1056/NEJMp1500523. Epub 2015 Jan 30.

5.

ERBB3-independent activation of the PI3K pathway in EGFR-mutant lung adenocarcinomas.

Song X, Fan PD, Bantikassegn A, Guha U, Threadgill DW, Varmus H, Politi K.

Cancer Res. 2015 Mar 15;75(6):1035-45. doi: 10.1158/0008-5472.CAN-13-1625. Epub 2015 Jan 16.

PMID:
25596284
6.

National Cancer Institute-supported clinical trials networks.

Abrams J, Kramer B, Doroshow JH, Varmus H.

J Clin Oncol. 2015 Jan 20;33(3):293. doi: 10.1200/JCO.2014.59.5421. Epub 2014 Dec 1. No abstract available.

PMID:
25452448
7.

Rescuing US biomedical research from its systemic flaws.

Alberts B, Kirschner MW, Tilghman S, Varmus H.

Proc Natl Acad Sci U S A. 2014 Apr 22;111(16):5773-7. doi: 10.1073/pnas.1404402111. Epub 2014 Apr 14.

8.

The Art and Politics of Science.

Varmus H.

New York: W.W. Norton & Company; 2009.

9.

Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer.

de Bruin EC, Cowell C, Warne PH, Jiang M, Saunders RE, Melnick MA, Gettinger S, Walther Z, Wurtz A, Heynen GJ, Heideman DA, Gómez-Román J, García-Castaño A, Gong Y, Ladanyi M, Varmus H, Bernards R, Smit EF, Politi K, Downward J.

Cancer Discov. 2014 May;4(5):606-19. doi: 10.1158/2159-8290.CD-13-0741. Epub 2014 Feb 17.

10.

DOK2 inhibits EGFR-mutated lung adenocarcinoma.

Berger AH, Chen M, Morotti A, Janas JA, Niki M, Bronson RT, Taylor BS, Ladanyi M, Van Aelst L, Politi K, Varmus HE, Pandolfi PP.

PLoS One. 2013 Nov 8;8(11):e79526. doi: 10.1371/journal.pone.0079526. eCollection 2013.

11.

Addressing the growing international challenge of cancer: a multinational perspective.

Varmus H, Kumar HS.

Sci Transl Med. 2013 Mar 6;5(175):175cm2. doi: 10.1126/scitranslmed.3005899.

PMID:
23467558
12.

Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins.

Lockwood WW, Zejnullahu K, Bradner JE, Varmus H.

Proc Natl Acad Sci U S A. 2012 Nov 20;109(47):19408-13. doi: 10.1073/pnas.1216363109. Epub 2012 Nov 5.

13.

Three decades of Wnts: a personal perspective on how a scientific field developed.

Nusse R, Varmus H.

EMBO J. 2012 Jun 13;31(12):2670-84. doi: 10.1038/emboj.2012.146. Epub 2012 May 22. Review.

14.

A conversation with Harold Varmus. Interview by Ushma S. Neill.

Varmus H.

J Clin Invest. 2012 Apr;122(4):1134-5. No abstract available.

15.

Science funding: Provocative questions in cancer research.

Varmus H, Harlow E.

Nature. 2012 Jan 25;481(7382):436-7. doi: 10.1038/481436a. No abstract available.

PMID:
22281578
16.

Ubiquitination, localization, and stability of an anti-apoptotic BCL2-like protein, BCL2L10/BCLb, are regulated by Ubiquilin1.

Beverly LJ, Lockwood WW, Shah PP, Erdjument-Bromage H, Varmus H.

Proc Natl Acad Sci U S A. 2012 Jan 17;109(3):E119-26. doi: 10.1073/pnas.1119167109. Epub 2012 Jan 10.

17.

Epstein-Barr virus: an important vaccine target for cancer prevention.

Cohen JI, Fauci AS, Varmus H, Nabel GJ.

Sci Transl Med. 2011 Nov 2;3(107):107fs7. doi: 10.1126/scitranslmed.3002878.

18.

Receptor for hyaluronan-mediated motility isoform B promotes liver metastasis in a mouse model of multistep tumorigenesis and a tail vein assay for metastasis.

Du YC, Chou CK, Klimstra DS, Varmus H.

Proc Natl Acad Sci U S A. 2011 Oct 4;108(40):16753-8. doi: 10.1073/pnas.1114022108. Epub 2011 Sep 21.

19.

Integrating cancer control into global health.

Varmus H, Trimble EL.

Sci Transl Med. 2011 Sep 21;3(101):101cm28. doi: 10.1126/scitranslmed.3002321. Review.

PMID:
21937755
20.

Superoxide dismutase 1 (SOD1) is a target for a small molecule identified in a screen for inhibitors of the growth of lung adenocarcinoma cell lines.

Somwar R, Erdjument-Bromage H, Larsson E, Shum D, Lockwood WW, Yang G, Sander C, Ouerfelli O, Tempst PJ, Djaballah H, Varmus HE.

Proc Natl Acad Sci U S A. 2011 Sep 27;108(39):16375-80. doi: 10.1073/pnas.1113554108. Epub 2011 Sep 19.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk